ARTICLE | Clinical News
QuatRx becocalcidiol Phase IIb psoriasis data
June 15, 2005 1:34 AM UTC
QuatRx (Ann Arbor, Mich.) said two doses of becocalcidiol ( QRX-101) met the primary endpoint of "clear" or "almost clear" of psoriatic lesions at eight weeks compared with vehicle in a Phase IIb tria...